News | April 20, 2026
Pharma stocks face Q4 reality check amid global headwinds
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Analysts expect modest revenue growth but pressure on profitability in the March quarter
Muted movement reflects consolidation phase as investors await earnings triggers
The company allocated €56 million to research and development for next-generation line solutions
The company reported net revenue of SEK 13.5 million for the full year 2025
At the center of deployment is mlHealth360’s proprietary Scaida AI platform, designed to detect and triage abnormalities in CT scans
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
Subscribe To Our Newsletter & Stay Updated
